ロード中...
Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-...
保存先:
| 出版年: | J Lipids |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hindawi
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889852/ https://ncbi.nlm.nih.gov/pubmed/29770231 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3179201 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|